Garima Kaushik is a distinguished Principal Scientist at Corellia AI, where she leverages her extensive expertise in cancer biology to spearhead innovative projects in antibody-drug conjugate (ADC) therapeutics. With a Ph.D. in Biochemistry and Molecular Biology, Garima has dedicated her career to advancing oncology research...
Garima Kaushik is a distinguished Principal Scientist at Corellia AI, where she leverages her extensive expertise in cancer biology to spearhead innovative projects in antibody-drug conjugate (ADC) therapeutics. With a Ph.D. in Biochemistry and Molecular Biology, Garima has dedicated her career to advancing oncology research and therapeutic development, focusing on the intricate mechanisms of cancer and the potential of targeted therapies. At Corellia AI, she leads ADC programs aimed at novel targets for both hematological and solid tumor indications, pushing the boundaries of current treatment paradigms.
One of Garima's key initiatives involves establishing a streamlined process for ADC target discovery and validation. This includes the meticulous development of target assessment studies that facilitate the identification of promising novel ADC candidates. Her expertise in antibody and ADC production, coupled with her proficiency in lead optimization and development, ensures that her projects not only meet scientific rigor but also align with industry standards for therapeutic efficacy and safety.
Garima's skill set is further enhanced by her strong organizational abilities and her proficiency in techniques such as immunohistochemistry and tissue culture, which are critical for validating therapeutic targets and assessing biological responses in preclinical models. Her commitment to public speaking and collaboration fosters a culture of knowledge sharing within her team and the broader scientific community, positioning her as a thought leader in the field of cancer therapeutics. Through her innovative approach and dedication to advancing ADC technology, Garima Kaushik is making significant strides in the fight against cancer, paving the way for more effective and targeted treatment options.
